GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (LTS:0IIM) » Definitions » Cyclically Adjusted FCF per Share

Esperion Therapeutics (LTS:0IIM) Cyclically Adjusted FCF per Share : $-4.25 (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Esperion Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Esperion Therapeutics's adjusted free cash flow per share for the three months ended in Sep. 2024 was $-0.182. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-4.25 for the trailing ten years ended in Sep. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 4.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 6.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Esperion Therapeutics was 15.70% per year. The lowest was 3.10% per year. And the median was 6.75% per year.

As of today (2024-12-13), Esperion Therapeutics's current stock price is $2.605. Esperion Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 was $-4.25. Esperion Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Esperion Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Esperion Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Esperion Therapeutics Cyclically Adjusted FCF per Share Chart

Esperion Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.65 -5.47 -5.63 -4.05 -4.47

Esperion Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.45 -4.47 -4.31 -4.20 -4.25

Competitive Comparison of Esperion Therapeutics's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Esperion Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Esperion Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Esperion Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Esperion Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.182/133.0289*133.0289
=-0.182

Current CPI (Sep. 2024) = 133.0289.

Esperion Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 -0.426 99.070 -0.572
201503 -0.450 99.621 -0.601
201506 -0.384 100.684 -0.507
201509 -0.529 100.392 -0.701
201512 -0.385 99.792 -0.513
201603 -0.435 100.470 -0.576
201606 -0.324 101.688 -0.424
201609 -0.634 101.861 -0.828
201612 -0.723 101.863 -0.944
201703 -1.522 102.862 -1.968
201706 -1.161 103.349 -1.494
201709 -1.476 104.136 -1.886
201712 -1.329 104.011 -1.700
201803 -1.625 105.290 -2.053
201806 -1.463 106.317 -1.831
201809 -1.400 106.507 -1.749
201812 -1.070 105.998 -1.343
201903 3.216 107.251 3.989
201906 -2.011 108.070 -2.475
201909 -2.149 108.329 -2.639
201912 -1.833 108.420 -2.249
202003 -2.527 108.902 -3.087
202006 4.811 108.767 5.884
202009 -3.111 109.815 -3.769
202012 -3.022 109.897 -3.658
202103 -3.427 111.754 -4.079
202106 -1.825 114.631 -2.118
202109 -2.615 115.734 -3.006
202112 -1.562 117.630 -1.766
202203 -0.640 121.301 -0.702
202206 -0.799 125.017 -0.850
202209 -0.632 125.227 -0.671
202212 -0.577 125.222 -0.613
202303 -0.693 127.348 -0.724
202306 -0.227 128.729 -0.235
202309 -0.173 129.860 -0.177
202312 -0.329 129.419 -0.338
202403 0.283 131.776 0.286
202406 -0.039 132.554 -0.039
202409 -0.182 133.029 -0.182

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Esperion Therapeutics  (LTS:0IIM) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Esperion Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Esperion Therapeutics Business Description

Traded in Other Exchanges
Address
3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Esperion Therapeutics Headlines

No Headlines